866-997-4948(US-Canada Toll Free)

Colorectal Cancer - UK Drug Forecasts and Treatment Analysis to 2020

Published By :

GlobalData

Published Date : Nov 2010

Category :

Cancer

No. of Pages : 152 Pages


GlobalData, the industry analysis specialist, has released its new report, Colorectal Cancer UK Drug Forecasts and Treatment Analysis to 2020. The report is an essential source of information and analysis on the UK colorectal cancer therapeutics market. The report provides comprehensive information on colorectal cancer, highlighting the treatment guidelines. It identifies and analyses the key trends shaping and driving the UK colorectal cancer therapeutics market. It analyses the treatment usage patterns in the UK colorectal cancer therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. The report provides valuable insights into the pipeline products within the global colorectal cancer sector. It quantifies the unmet need in the UK colorectal cancer therapeutics market, highlighting the opportunity for future players. 

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalDatas team of industry experts. 

Scope

The scope of the report includes: 

  • An overview of colorectal cancer which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
  • Annualized UK colorectal cancer therapeutics market revenue, annual cost of therapy and treatment usage patterns data from 2001 to 2009, forecast for 11 years to 2020. 
  • Insightful review of the key industry drivers, restraints and challenges and predicted impact of key events. 
  • Competitor assessment including drug launch analysis and drug sales forecasts.
  • Product profiles covering efficiency, safety, clinical study details, annual cost, regulatory approvals, LCM activities and drug sales forecast.
  • Analysis of unmet need in the market and target product profile including opportunity for target product. 
  • Technology trends analytic framework to assess strength of pipeline. 
  • Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include EGFR inhibitors, VEGF inhibitors, monoclonal antibodies, angiogenesis inhibitors and others.
  • An overview of the most promising drugs including clinical study details, efficacy, safety, collaboration agreements, marketing rights and launch analysis.
  • Analysis of the current and future market competition in the UK Colorectal Cancer therapeutics market. Company profiles including business description, financial overview and SWOT analysis. Key future market players covered include Hoffmann-La Roche Ltd, Bristol-Myers Squibb, Eli Lilly, Sanofi-Aventis, Debiopharm Group and Merck KGaA.
  • Analysis of licensing agreements during 2004-2010 in the colorectal cancer therapeutics market. M&A analysis which includes M&A deals by size and geography.
  • Strategic assessment of the market through market impact analysis, future market scenario and company analysis.
  • Direct quotes from key opinion leaders (KOL) or physicians in the colorectal cancer therapeutics market in the UK.

Reasons to buy

The report will enhance your decision making capability. It will allow you to:

  • Develop business strategies and perform superior market quantification analysis by 
  • Understanding the trends shaping and driving the UK colorectal cancer therapeutics market. 
  • Understanding treatment preferences of physicians in disease state and across treatment flow.
  • Accessing market sizing, forecasts and quantified growth opportunities in the UK colorectal cancer therapeutics market till 2020.
  • Quantifying patient population in the UK to better design product pricing & launch plans.
  • Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape by
  • Performing benchmarking analysis and growth opportunities against currently marketed products
  • Identifying market entry points based on safety, efficacy, and pricing parameters. 
  • Assessing competitiveness of products in market by understanding the strength and weakness of current competition. 
  • Develop and design your in-licensing and out-licensing strategies by 
  • Taking a comprehensive look of at the disease pipeline and identifying most promising paradigm shifting products.
  • Assessing strength of pipeline bases on first in class, me-too, generic and lifecycle management of products.
  • Track drug sales in the UK colorectal cancer therapeutics market from 2001 to 2020
  • Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. 
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.
  • Whats the next big thing in the UK Colorectal Cancer therapeutics market landscape? Identify, understand and capitalize.
Table Of Content

1 Table of contents 3
1.1 List of Tables 6
1.2 List of Figures 7

2 Disease Overview 9
2.1 Overview 9
2.2 Epidemiology 10
2.3 Etiology 10
2.4 Symptoms 11
2.4.1 Colon Cancer 11
2.4.2 Rectal Cancer 11
2.5 Diagnosis 12
2.5.1 FOBT 12
2.5.2 Endoscopy 12
2.5.3 Optical Colonoscopy 13
2.5.4 Virtual Colonoscopy 13
2.5.5 Double Contrast Barium Enema (DCBE) 13
2.6 Pathology 13
2.6.1 Grading 14
2.7 Treatment 14
2.7.1 Colon Cancer Treatment by Stage 15
2.7.2 Rectal Cancer Treatment by Stage 17
2.7.3 Chemotherapy Options 19
2.8 Treatment Guidelines 22

3 Market Characterization 23
3.1 The UK 23
3.1.1 Market Size 23
3.1.2 Drivers and Barriers 28
3.1.3 Impact on the Market 30
3.1.4 Forecasts 31
3.1.5 Drug Sales 37
3.1.6 Pricing and Reimbursements 39
3.2 Key Takeaway 40

4 Competitor Assessment 41
4.1 Strategic Competitor Assessment 41
4.1.1 Overview 41
4.1.2 Benchmarking 41
4.1.3 Current Competitor Assessment 44
4.2 Launch Analysis and Sales Forecasts 45
4.2.1 Market Share Analysis of Drugs 45
4.3 Product Profiles 46
4.3.1 Avastin (bevacizumab) 47
4.3.2 Erbitux (cetuximab) 50
4.3.3 Xeloda (capecitabine) 55
4.3.4 Vectibix (panitumumab) 59
4.3.5 Eloxatin (oxaliplatin) 64
4.3.6 Camptosar (irinotecan) 69
4.3.7 Fluorouracil (5-FU) 71
4.3.8 Leucovorin (folinic acid) 72
4.4 Key Takeaway 73

5 Pipeline Assessment 74
5.1 Overview 74
5.2 Pipeline Analysis by Phase of Development 75
5.3 Pipeline by Mechanism of Action 76
5.4 Strategic Pipeline Assessment 77
5.4.1 Technology Trends Analytical Framework 77
5.5 Trends in Colorectal Cancer Pipeline 78
5.5.1 Increase in the Number of Vaccines in R&D Targeted at Stage III Colorectal Cancer 78
5.5.2 Novel First-in-Class Molecules in Late-stage Clinical Development Strengthening the Pipeline 78
5.5.3 Failure of key Molecules in Phase II and Phase III Development 78
5.6 Partners in Development 79
5.6.1 Licensing Agreements by Phase of Development 79
5.6.2 Licensing Agreements by Geography 81
5.6.3 Licensing Agreements: Colorectal Cancer Screening / Diagnostic Technology 82
5.7 Most Promising Drugs Profiles 83
5.7.1 Aflibercept 83
5.7.2 Brivanib 85
5.7.3 OncoVAX 87
5.7.4 TroVax 89
5.7.5 KRX-0401 (Perifosine) 91
5.8 Colorectal Cancer Pipeline Preclinical Phase 93
5.9 Colorectal Cancer Pipeline Phase I 93
5.10 Colorectal Cancer Pipeline Phase II 95
5.11 Colorectal Cancer Pipeline Phase III 101
5.12 Key Takeaway 103

6 Unmet Need and Target Product Profile 104
6.1 Unmet Need 105
6.2 Opportunity for Target Product 106
6.3 Target Product Profile 107
6.3.1 Ideal Characteristics 107
6.3.2 Target Product Description 107
6.4 Key Takeaway 108

7 Strategic Assessment 109
7.1 Key Events Impacting the Future Market 109
7.2 Market Impact Analysis 109
7.3 Future Market Scenario 110
7.4 Company Analysis 111
7.4.1 Market Leadership 111
7.4.2 Future Players in the Market 111
7.5 Key Takeaway 111

8 Company Profiles 112
8.1 F. Hoffmann La Roche 112
8.1.1 Business Description 112
8.1.2 Financial Overview 112
8.1.3 SWOT Analysis 112
8.2 Bristol-Myers Squibb 114
8.2.1 Business Description 114
8.2.2 Financial Overview 114
8.2.3 SWOT Analysis 115
8.3 Sanofi-Aventis 116
8.3.1 Business Description 116
8.3.2 Financial Overview 116
8.3.3 SWOT Analysis 116
8.4 Debiopharm Group 117
8.4.1 Business Description 117
8.5 Merck KGaA 117
8.5.1 Business Description 117
8.5.2 Financial Overview 118
8.5.3 SWOT Analysis 118
8.6 Regeneron 119
8.6.1 Business Description 119
8.6.2 Financial Overview 120
8.6.3 SWOT Analysis 120
8.7 Vaccinogen BD 121
8.7.1 Overview 121
8.7.2 SWOT Analysis 122
8.8 Oxford BioMedica 122
8.8.1 Business Description 122
8.8.2 Financial Overview 123
8.8.3 SWOT Analysis 124
8.9 Auron Healthcare GmbH 125
8.9.1 Company Overview 125
8.10 AEterna Zentaris 125
8.10.1 Business Description 125
8.10.2 Financial Overview 125
8.10.3 SWOT Analysis 126
8.11 Keryx 128
8.11.1 Business Description 128
8.11.2 Financial Overview 129
8.11.3 SWOT Anlaysis 129
8.12 Abbott Laboratories 131
8.12.1 Business Description 131
8.12.2 Financial Performance 132
8.12.3 SWOT Analysis 132
8.13 Pfizer 134
8.13.1 Business Description 134
8.13.2 Financial Overview 135
8.13.3 SWOT Analysis 135
8.14 Light Sciences Oncology, Inc 136
8.14.1 Business Description 136
8.14.2 Financial Overview 136
8.14.3 SWOT Analysis 136

9 Deals Analysis 139
9.1 Key Highlights 139
9.2 Key Deals Analysis 140
9.2.1 Eli Lilly Acquires ImClone 140
9.2.2 Astellas Pharma Acquires OSI Pharmaceuticals 140
9.2.3 Takeda Acquires IDM Pharma 140
9.2.4 Alchemia Acquires Meditech 140
9.2.5 Sanofi-Aventis Acquired Additional 15% Stake in Regeneron 140
9.2.6 BBM Holdings to Acquire YM Biosciences 140
9.2.7 Pfizer Acquires Assets of Campto from Sanofi-Aventis 140
9.2.8 Peptech Acquires cancer Antibodies from Scancell 141
9.2.9 Quest Pharma Tech Inc. Acquired Late Stage Immunotherapy Product Pipeline of Paladin Labs 141
9.2.10 Spectrum Pharmaceuticals Inc Acquired Oncology Drug Assets from Targent Inc 141
9.3 Deals Analysis by Geography 141
9.4 Deals Analysis by Deal Size 142

10 Expert Opinion 143
10.1 UK 143

11 Appendix 144
11.1 Market Definitions 144
11.2 Abbreviations 144
11.3 Research Methodology 146
11.3.1 Coverage 146
11.3.2 Secondary Research 147
11.3.3 Forecasting 147
11.3.4 Primary Research 150
11.3.5 Expert Panel validation 150
11.3.6 Contact Us 150
11.3.7 Disclaimer 150
11.3.8 Sources 151

List of Table


Table 1: Colorectal Cancer Therapeutics Market, Global, Staging of Colorectal Cancer, 2010 10
Table 2: Colorectal Cancer Therapeutics Market, Global, WHO Classification of Colorectal Carcinomas, 2010 14
Table 3: Colorectal Cancer Therapeutics Market, The UK, Sales Value ($bn), 20012009 23
Table 4: Colorectal Cancer Therapeutics Market, The UK, Annual Cost of Therapy ($), 20012009 24
Table 5: Colorectal Cancer Therapeutics Market, The UK, Patient Volume (000), 20012009 25
Table 6: Colorectal Cancer Therapeutics Market, The UK, Treatment Usage Patterns, 20012009 26
Table 7: Colorectal Cancer, The UK, Sales Value ($bn), 20092020 31
Table 8: Colorectal Cancer Therapeutics Market, The UK, Annual Cost of Therapy ($), 20092020 32
Table 9: Colorectal Cancer Therapeutics Market, The UK, Patient Volume, 20092020 33
Table 10: Colorectal Cancer Therapeutics Market, The UK, Treatment Usage Patterns (000), 20092020 34
Table 11: Colorectal Cancer Therapeutics Market, The UK, Drug Sales ($m), 2001-2020 (Part 1) 38
Table 12: Colorectal Cancer Therapeutics Market, The UK, Drug Sales ($m), 2001-2020 (Part 2) 39
Table 13: Colorectal Cancer, Global, Safety Profile of Standard Treatment, 2010 43
Table 14: Colorectal Cancer Therapeutics Market, Global, Benchmarking Major Marketed Products, 2010 46
Table 15: Colorectal Cancer, Global, Avastin Adverse Effects Incidence, 2010 48
Table 16: Colorectal Cancer Therapeutics Market, The UK, Erbitux, Incidence of Adverse Effects, 2010 51
Table 17: Colorectal Cancer Therapeutics Market, The UK, Xeloda, Adverse Effects Incidence, 2010 56
Table 18: Colorectal Cancer Therapeutics Market, The UK, Vectibix, PRECEPT Interim Results, 2010 60
Table 19: Colorectal Cancer Therapeutics Market, The UK, Vectibix, Incidence of Adverse Events, 2010 61
Table 20: Colorectal Cancer Therapeutics Market, The UK, Eloxatin, Efficacy, 2010 65
Table 21: Colorectal Cancer Therapeutics Market, The UK, Eloxatin, Incidence of Adverse Events, 2010 66
Table 22: Colorectal Cancer Therapeutics Market, Global, Technology Licensing Agreements Description, 2010 82
Table 23: Colorectal Cancer Therapeutics Market, The UK, Preclinical Phase Pipeline, July 2010 93
Table 24: Colorectal Cancer, The UK, Phase I Pipeline, July 2010 93
Table 25: Colorectal Cancer, The UK, Phase II Pipeline, July 2010 95
Table 26: Colorectal Cancer, The UK, Phase III Pipeline, July 2010 101
Table 27: Colorectal Cancer Therapeutics Market, The UK, Commonly Prescribed Treatment Options, 2010 105
Table 28: Colorectal Cancer Therapeutics Market, The UK, Characteristics of Ideal Drug Which Satisfies the Unmet Needs, 2010 107
Table 29: Colorectal Cancer Therapeutics Market, The UK, Description of Ideal Drug Which Satisfies the Unmet Needs, 2010 107

List of Chart


Figure 1: Colorectal Cancer, Global, Colon Cancer Treatment Guidelines, 2010 22
Figure 2: Colorectal Cancer, Global, Rectal Cancer Treatment Guidelines, 2010 22
Figure 3: Colorectal Cancer Therapeutics Market, The UK, Sales Value ($bn), 20012009 23
Figure 4: Colorectal Cancer Therapeutics Market, The UK, Annual Cost of Therapy ($), 20012009 24
Figure 5: Colorectal Cancer Therapeutics Market, The UK, Patient Volume (absolute), 20012009 25
Figure 6: Colorectal Cancer Therapeutics Market, The UK, Treatment Usage Patterns, 20012009 26
Figure 7: Colorectal Cancer Therapeutics Market, The UK, Market Drivers and Restraints, 2009 28
Figure 8: Colorectal Cancer Therapeutics Market, The UK, The Impact of Historical Events on the Market, 2010 30
Figure 9: Colorectal Cancer Therapeutics Market, The UK, Sales Value ($bn), 20092020 31
Figure 10: Colorectal Cancer, The UK, Annual Cost of Therapy ($), 20092020 32
Figure 11: Colorectal Cancer Therapeutics Market, The UK, Patient Volume, 20092020 33
Figure 12: Colorectal Cancer Therapeutics Market, The UK, Treatment Usage Patterns, 20092020 34
Figure 13: Colorectal Cancer Therapeutics Market, The UK, Future Market Drivers and Restraints, 20092020 36
Figure 14: Colorectal Cancer Therapeutics Market, The UK, Drug Sales ($m), 2001-2020 37
Figure 15: Colorectal Cancer Therapeutics Market, Global, Clinical Endpoints for Benchmarking, 2010 42
Figure 16: Colorectal Cancer Therapeutics Market, The UK, Strategic Competitor Assessment of Major Marketed Drugs, 2010 44
Figure 17: Colorectal Cancer Therapeutics Market, The UK, Sales Forecast Split by Therapies, 2001-2020 45
Figure 18: Colorectal Cancer Therapeutics Market, Global, Avastin, Life Cycle Management Activities, 20042010 49
Figure 19: Colorectal Cancer Therapeutics Market, The UK, Avastin, Sales Forecast ($m), 2009-2020 50
Figure 20: Colorectal Cancer Therapeutics Market, Global, Erbitux, Life Cycle Management Activities, 20042010 53
Figure 21: Colorectal Cancer Therapeutics Market, The UK, Erbitux, Sales Forecast ($m), 2009-2020 54
Figure 22: Colorectal Cancer Therapeutics Market, The UK, Xeloda, Chemical Structure, 2010 55
Figure 23: Colorectal Cancer Therapeutics Market, Global, Xeloda, Life Cycle Management Activities, 2010 58
Figure 24: Colorectal Cancer Therapeutics Market, The UK, Xeloda, Sales Forecast ($m), 2001-2020 59
Figure 25: Colorectal Cancer Therapeutics Market, Global, Vectibix, Life Cycle Management Activities, 2010 63
Figure 26: Colorectal Cancer Therapeutics Market, The UK, Vectibix, Sales Forecast ($m), 2008-2020 64
Figure 27: Colorectal Cancer Therapeutics Market, The UK, Eloxatin, Chemical Structure, 2010 65
Figure 28: Colorectal Cancer Therapeutics Market, Global, Eloxatin, Life Cycle Management Activities, 2010 67
Figure 29: Colorectal Cancer Therapeutics Market, The UK, Eloxatin, Sales Forecast ($m), 2004-2020 68
Figure 30: Colorectal Cancer Therapeutics Market, The UK, Camptosar, Chemical Structure 69
Figure 31: Colorectal Cancer Therapeutics Market, Global, Camptosar, Life Cycle Management Activities, 2010 70
Figure 32: Colorectal Cancer Therapeutics Market, The UK, Camptosar, Sales Forecast ($m), 2001-2020 71
Figure 33: Colorectal Cancer Therapeutics Market, The UK, Fluorouracil, Chemical Structure 71
Figure 34: Colorectal Cancer Therapeutics Market, The UK, Leucovorin, Chemical Structure 72
Figure 35: Colorectal Cancer Therapeutics Market, Global, Clinical Trials by Therapy (%), 2010 74
Figure 36: Colorectal Cancer Therapeutics Market, Global, Clinical Trials by Phase of Development (%), 2010 75
Figure 37: Colorectal Cancer Therapeutics Market, Global, Pipeline by Mechanism of Action, 2010 76
Figure 38: Colorectal Cancer Therapeutics Market, Global, Technology Trends Analytic Framework of Pipeline Drugs, 2010 77
Figure 39: Colorectal Cancer Therapeutics Market, Global, Technology Trends Description of Pipeline Drugs, 2010 78
Figure 40: Colorectal Cancer Therapeutics Market, Global, Licensing Agreements by Phase of Development (%), 2004-2010 79
Figure 41: Colorectal Cancer Therapeutics Market, Global, Licensing Agreements by Geography (%), 2010 81
Figure 42: Colorectal Cancer Therapeutics Market, Global, Licensing Agreements by Screening/Diagnostic Technology (%), 2010 82
Figure 43: Colorectal Cancer Therapeutics Market, The UK, Aflibercept Sales Forecast ($m), 2011-2020 85
Figure 44: Colorectal Cancer Therapeutics Market, The UK, Brivanib Chemical Structure, 2010 85
Figure 45: Colorectal Cancer Therapeutics Market, The UK, Brivanib Sales Forecasts ($m), 2013-2020 87
Figure 46: Colorectal Cancer Therapeutics Market, The UK, OncoVAX Sales Forecast ($m), 2011-2020 89
Figure 47: Colorectal Cancer Therapeutics Market, The UK, TroVax Sales Forecast ($m), 2014-2020 91
Figure 48: Colorectal Cancer Therapeutics Market, The UK, Perifosine Chemical Structure, 2010 91
Figure 49: Colorectal Cancer Therapeutics Market, The UK, Median Overall Survival for Metastatic Colorectal Cancer Patients (months), 2010 104
Figure 50: Colorectal Cancer Therapeutics Market, The UK, Opportunity and Unmet Need, 2010 106
Figure 51: Colorectal Cancer, The UK, Key Events Impacting the Future Market 109
Figure 52: Colorectal Cancer Therapeutics Market, The UK, Implications for Future Market Competition, 2010 110
Figure 53: Colorectal Cancer Therapeutics Market, Global, Merger and Acquisition Deals by Geography, 2010 139
Figure 54: Colorectal Cancer Therapeutics Market, Global, Merger and Acqusition Deals by Geography (%), 2010 141
Figure 55: Colorectal Cancer Therapeutics Market, Global, Merger and Acquisition Deals by Deal Size (%), 2010 142
Figure 56: Colorectal Cancer Therapeutics Market, The UK, Key Data Inputs from Key Opinion Leader Interviews, July 2010 143
Figure 57: GlobalData Market Forecasting Model 149

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *